A Q&A with Devora Allon

Earlier this month, a federal jury in San Francisco absolved Gilead Sciences and Teva Pharmaceuticals of allegations they entered into an illegal pay-for delay settlement related to a pair of HIV treatments. GCR USA spoke to Kirkland & Ellis partner Devora Allon, co-lead counsel to Gilead, on how the drugmaker escaped the potential of facing billions in damages.

Unlock unlimited access to all Global Competition Review content